• The Scientist
    THLD Th-302 OS panc CA data likely to b > Abraxane OS. Abrax trial began 3/09. Near end of trial on 9/11, protocol changed and added 210 pts
    Reply (3)
    • The Scientist: Likely had to add pts because initial OS data on 630 pts was not good. If OS #s good, absolutely no reason to add pts to trial
    • The Scientist: Th-302 targets hypoxic niche, which should also kill CSCs.
    • Noreika: OT- That was a bummer yesterday that Bapi got cancelled. I really thought the Apo4 non-carriers would have some positive news.